Spark Therapeutics plans to file for U.S. regulatory approval next year for the first gene therapy product on the market in the U.S.» Read More
Doctors outside of insurance plan networks charge several times what Medicare would pay.
The fight for Planned Parenthood funding is far from over, says patient and advocate Dayna Ferris-Fisher.
Biotech stocks surged on Wednesday, and according to one trader, there are more gains ahead.
The real problem with biotech has to do with the size of biotech firms, says industry CEO Robert Mulroy. Here's why.
Sixty percent of people oppose the Obamacare levy on high-cost health plans — at first.
The most popular prescription drug plans will see an average price hike of 8 percent next year.
With the IBB performing poorly and increased confusion in the biotech market, is it time for investors to be bullish?
Hillary Clinton will speak out against the so-called Cadillac tax on certain health care plans. The NYT reports.
Many women with early-stage breast cancer can skip chemotherapy without hurting their odds of beating the disease.
Turing Pharmaceuticals may have been an egregious example of overnight drug price hikes, but it's not the only one raising eyebrows.
Democrats are pressing a Republican committee chairman to force Valeant to turn over documents tied to price hikes imposed earlier this year.
JPMorgan reached out to fund managers to find out their current concerns and analyze the prospects for the biotech sector.
Biotechnology stocks deepened their rout Friday, as fears of drugs prices continued to mount.
John Maraganore of Alnylam Pharmaceuticals tells CNBC his industry focuses on innovation, not pushing prices on decades-old drugs higher to make a profit.
Most companies now offer health coverage that requires employees to pay an annual deductible before insurance kicks in, and the size of that deductible has soared in the past decade, a study finds.
Martin Shkreli was accused by an ex-employee of contacting the man's family repeatedly during a lawsuit.
A huge overnight price increase for an important tuberculosis drug has been rescinded after a public outcry, the NYT reports.
Hillary Clinton is laying out a new plan to rein in the rising cost of prescription drugs, seeking to build upon Obamacare.
Reckitt Benckiser, the maker of Durex condoms, is calling on India to axe price controls on its products, the FT reports.
Members of Congress from both parties are calling for changes in the Affordable Care Act to stop rising premiums. The NYT reports.
Get the best of CNBC in your inbox